The overall survival rate of neuroblastoma patients with ecDNA-derived rearrangements is significantly lower than that of patients without ecDNA-derived rearrangements, and the overall survival rate of patients with MYCN ecDNA-derived rearrangements is also significantly lower than that of patients without MYCN ecDNA-derived rearrangements (96). This evidence concerns the gene MYCN and neuroblastoma.